07:30 AM EST, 12/17/2024 (MT Newswires) -- IDEAYA Biosciences ( IDYA ) said Tuesday an independent data monitoring committee has recommended a move-forward dose for a potential registration-enabling phase 2/3 trial to evaluate the company's darovasertib combined with Pfizer's ( PFE ) crizotinib in patients with a certain metastatic uveal melanoma.

Chief Medical Officer Darrin Beaupre said the committee's recommendation allows the company to complete the part 2a of the trial and continue to enroll in part 2b.